Enanta Pharmaceuticals, Inc. (ENTA) Income Statement
ENTA FY2025 at a glance
Fiscal year ended September 30, 2025 · U.S. dollarsENTA revenue and net income
Where ENTA's revenue goes
FY2025Each bar shows an amount and its share of revenue. ENTA kept −125.4% of revenue as net income.
ENTA profit margins
ENTA growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −3.4% | −8.8% | −11.8% | −8.6% |
| Gross profit | −10.2% | −11.0% | −13.1% | −9.3% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ENTA quarterly EPS vs estimates
Enanta Pharmaceuticals beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 16, 2026 (estimate $-0.82).
ENTA income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.3M | $67.6M | $79.2M | $86.2M | $97.1M | $122.5M | $205.2M | $206.6M | $102.8M | $88.3M |
| Cost of revenue | $4.6M | $0 | $2.4M | $3.0M | $0 | $0 | $0 | $115.8M | $76.1M | $55.8M |
| Gross profit | $60.7M | $67.6M | $79.2M | $86.2M | $97.1M | $122.5M | $205.2M | $206.6M | $102.8M | $88.3M |
| Research & development | $106.7M | $131.5M | $163.5M | $164.5M | $174.1M | $136.8M | $142.2M | $94.9M | $57.5M | $40.5M |
| Sales, general & admin | $43.9M | $57.9M | $52.9M | $45.5M | $32.5M | $27.4M | $26.2M | $23.4M | $20.7M | $17.0M |
| Total operating expenses | $146.1M | $189.3M | $216.4M | $210.0M | $206.6M | $164.1M | $168.5M | $118.3M | $78.2M | $57.4M |
| Operating income | −$85.3M | −$121.7M | −$137.2M | −$123.8M | −$109.6M | −$41.6M | $36.7M | $88.3M | $24.6M | $30.8M |
| Interest income | $9.4M | $14.8M | $11.4M | $1.6M | $2.0M | $6.5M | $8.8M | $4.8M | $2.5M | $1.7M |
| Interest expense | $7.7M | $10.9M | $5.1M | $1.6M | $5.3M | $10.3M | $8.8M | $4.9M | $40,000 | $45,000 |
| Income before taxes | −$83.5M | −$117.8M | −$131.0M | −$122.2M | −$107.6M | −$35.0M | $45.6M | $93.1M | $26.9M | $32.6M |
| Income taxes | −$1.7M | −$1.7M | $2.8M | −$433,000 | −$28.6M | $1.1M | −$826,000 | $21.2M | $9.2M | $10.9M |
| Net income | −$81.9M | −$116.0M | −$133.8M | −$121.8M | −$79.0M | −$36.2M | $46.4M | $72.0M | $17.7M | $21.7M |
| EBITDA | −$70.8M | −$104.5M | −$123.5M | −$119.2M | −$106.2M | −$38.0M | $40.0M | $90.8M | $26.8M | $32.5M |
| EPS (diluted) | −$3.83 | −$5.48 | −$6.37 | −$5.91 | −$3.91 | −$1.82 | $2.22 | $3.28 | $0.88 | $1.12 |
| Gross margin | 93.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −130.7% | −179.9% | −173.2% | −143.7% | −112.9% | −34.0% | 17.9% | 42.7% | 23.9% | 34.9% |
| Net margin | −125.4% | −171.6% | −169.0% | −141.3% | −81.4% | −29.5% | 22.6% | 34.8% | 17.2% | 24.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.4M | $17.2M | $18.6M | $15.1M | $18.3M | $14.9M | $17.0M | $14.6M | $18.0M | $17.1M | $18.0M | $18.9M |
| Cost of revenue | $1.2M | $1.2M | $0 | $1.3M | $0 | $1.2M | $889,000 | $479,000 | $594,000 | $621,000 | $642,000 | $669,000 |
| Gross profit | $14.4M | $15.9M | $18.6M | $15.1M | $18.3M | $14.9M | $17.0M | $14.6M | $18.0M | $17.1M | $18.0M | $18.9M |
| Research & development | $22.1M | $19.4M | $20.9M | $23.8M | $27.2M | $28.1M | $27.7M | $30.8M | $28.7M | $35.6M | $36.4M | $36.2M |
| Sales, general & admin | $9.5M | $9.6M | $9.0M | $9.7M | $10.0M | $11.4M | $12.8M | $13.7M | $14.0M | $14.2M | $16.5M | $13.8M |
| Total operating expenses | $31.6M | $27.8M | $29.9M | $33.5M | $37.2M | $39.5M | $40.5M | $44.5M | $42.2M | $49.8M | $52.9M | $50.0M |
| Operating income | −$17.2M | −$11.9M | −$11.3M | −$18.4M | −$18.9M | −$24.5M | −$23.5M | −$29.9M | −$24.2M | −$32.8M | −$34.9M | −$31.0M |
| Interest income | $1.9M | $2.1M | $2.4M | $2.1M | $2.3M | $2.3M | $2.8M | $3.2M | $3.5M | $3.8M | $4.3M | $4.7M |
| Interest expense | $4.1M | $3.3M | $3.1M | $2.4M | $1.6M | $1.7M | $2.0M | $2.6M | $2.4M | $2.6M | $3.4M | $3.2M |
| Income before taxes | −$19.5M | −$13.1M | −$11.9M | −$18.7M | −$18.2M | −$23.9M | −$22.7M | −$29.2M | −$23.1M | −$31.5M | −$34.0M | −$29.5M |
| Income taxes | $36,000 | $7,000 | $24,000 | $32,000 | $29,000 | −$1.3M | −$416,000 | −$363,000 | −$395,000 | −$363,000 | −$622,000 | −$1.4M |
| Net income | −$19.5M | −$13.1M | −$11.9M | −$18.7M | −$18.3M | −$22.6M | −$22.3M | −$28.8M | −$22.7M | −$31.2M | −$33.4M | −$28.1M |
| EBITDA | −$14.2M | −$8.6M | −$7.6M | −$15.0M | −$15.4M | −$21.0M | −$19.9M | −$26.1M | −$20.1M | −$28.3M | −$29.9M | −$25.7M |
| EPS (diluted) | −$0.67 | −$0.45 | −$0.42 | −$0.87 | −$0.85 | −$1.06 | −$1.05 | −$1.36 | −$1.07 | −$1.47 | −$1.58 | −$1.33 |
| Gross margin | 100.0% | 93.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −120.0% | −69.1% | −60.5% | −121.6% | −103.2% | −164.3% | −138.8% | −204.4% | −134.6% | −192.1% | −193.8% | −163.9% |
| Net margin | −135.8% | −76.3% | −64.1% | −123.6% | −99.7% | −151.7% | −131.4% | −197.3% | −126.1% | −182.7% | −185.6% | −148.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ENTA's financial statements (latest annual report filed November 19, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ENTA financial results
In fiscal year 2025 (ended September 30, 2025), Enanta Pharmaceuticals reported revenue of $65.3 million, down 3.4% from the year before. It had a net loss of $81.9 million, a net profit margin of −125.4%. Diluted earnings per share came to −$3.83. Over five years revenue grew at an average rate of −11.8% a year.
See the ENTA stock overview for the latest quote and news, or the ENTA chart for price history and technical indicators.
ENTA income statement FAQ
What is Enanta Pharmaceuticals's annual revenue?
Enanta Pharmaceuticals reported total revenue of $65.3 million for fiscal year 2025, which ended on September 30, 2025. That was down 3.4% from $67.6 million the previous year.
Is Enanta Pharmaceuticals profitable?
No. Enanta Pharmaceuticals reported a net loss of $81.9 million in fiscal 2025, a net profit margin of −125.4%; its operating margin was −130.7%.
What is Enanta Pharmaceuticals's gross margin?
Enanta Pharmaceuticals's gross margin was 93.0% in fiscal 2025: for every $100 of revenue, Enanta Pharmaceuticals kept $93 after the direct cost of its products and services.
How much does Enanta Pharmaceuticals spend on research and development?
Enanta Pharmaceuticals spent $106.7 million on research and development in fiscal 2025, 163.4% of revenue.
How fast is Enanta Pharmaceuticals growing?
Revenue grew −11.8% a year on average over the last five fiscal years, from $122.5 million to $65.3 million.
What are Enanta Pharmaceuticals's earnings per share?
Enanta Pharmaceuticals earned $-3.83 per diluted share in fiscal 2025, compared with $-5.48 a year earlier.
When will Enanta Pharmaceuticals report its next earnings?
Enanta Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 16, 2026 after the market closes.
When does Enanta Pharmaceuticals's fiscal year end?
Enanta Pharmaceuticals's fiscal year ends in September. The latest annual report covers the year ended September 30, 2025 and was filed on November 19, 2025.